查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1977203

醫藥和生物技術領域臨床階段合作條款及協議（2020-2026）

Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026
出版日期: | 出版商: Current Partnering | 英文 1000+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

本報告對醫藥和生物技術領域的臨床階段合作條款及協議進行了全面、數據驅動的分析，深入剖析了企業簽訂臨床階段合作協議的背景和原因，以及影響這些合作的財務和戰略因素。這份產業必備的資源提供了關於臨床階段藥物研發合作中合約結構、談判動態和財務考量的獨到見解。

臨床階段授權協議通常授予被授權人獨家開發授權人產品或技術的權利或選擇權，通常涵蓋I期、II期和III期臨床試驗。這些協議往往形式複雜，包含聯合研發、共同開發和商業化策略等多個要素。

本報告詳細介紹了醫療保健領域最新的臨床階段協議，幫助企業評估市場趨勢、優化談判策略並建立合約結構基準。

生技與製藥業經銷商的必備資源

"製藥和生物技術領域臨床階段合作條款和協議" 報告是參與生物製藥交易的業務拓展、法律和財務專業人士不可或缺的資訊來源。

憑藉全面的洞察、龐大的交易資料庫以及對合約文件的直接訪問，本報告是以下用途的終極工具：

  • 交易結構與財務條款基準分析
  • 優化談判策略
  • 評估潛在合作夥伴的彈性
  • 識別臨床階段合作的趨勢
  • 為什麼本報告對經銷商至關重要
  • 在建立臨床階段合作關係時，了解潛在合作夥伴的靈活性和談判策略至關重要。主要財務條款（例如，預付款、里程碑付款、特許權使用費）只是概要；合約文件明確規定了這些付款的實際觸發條件和條件，而這些細節往往在新聞稿和傳統交易資料庫中缺失。
  • 本報告全面涵蓋了自 2020 年以來發布的 1,859 份臨床階段合作協議，包括可用的財務條款。報告還提供了指向線上合約記錄和向美國證券交易委員會 (SEC) 提交的公開合約文件的直接連結。
  • 分析這些協議能夠幫助企業獲得關鍵訊息，從而優化其交易策略、評估合作夥伴的靈活性並制定具有競爭力的合約。
  • 臨床階段合作趨勢的全面分析

本報告的第一章詳細解釋了臨床階段合作的運作方式。內容如下：

第一章 - 本報告簡介

第二章 - 企業為何參與臨床階段合作

第三章 - 策略方法與合約結構（附個案研究）

第四章 - 付款策略，包括預付款、里程碑付款和特許權使用費

第五章 - 依年份、研發階段、治療領域、技術類型和主要承包商分析臨床階段合約活動

第六章 - I期、II期和III期合約的總金額、預付款、里程碑完成條件和特許權使用費率的詳細財務分析

第七章 - 主要臨床階段合約的總金額回顧

第八章 - 頂尖承包商簡介 25家最活躍的臨床階段交易管理公司

第九章 - 臨床階段合作協議資料庫（包括可用合約文件）

第十章 - 依I期、II期和III期分類的臨床階段協議綜合目錄

  • 本報告的主要優勢

這份產業必備資源提供獨家見解，幫助企業評估、建構和談判其臨床階段合作。主要優點包括：

  • 無與倫比的市場洞察 - 深入了解塑造2020年後製藥和生物技術產業的臨床階段交易趨勢。
  • 取得獨家財務數據 - 透過取得合約總價值、預付款、里程碑付款結構和特許權使用費條款等信息，在合約談判中獲得競爭優勢。
  • 全面的合約資料庫 - 存取 1,859 份精心挑選的臨床階段協議（包括可用的合約文件），提供無與倫比的透明度和基準分析。
  • 深入分析產業領導者 - 分析全球排名前 25 名的製藥、生物技術和新興生物製藥公司實際簽署的臨床階段協議。
  • 經過驗證的案例研究和結構分析 - 驗證真實世界的合約結構和案例研究，以完善您自身的合作和談判策略。
  • 識別高價值交易 - 識別自 2020 年以來達成的最具盈利性的臨床階段協議，並深入了解行業中的優質交易。
  • 分析最活躍的交易撮合者 - 識別推動臨床階段合作的關鍵人物，確保您找到合適的合作夥伴。
  • 策略交易地圖 - 全面了解臨床階段協議，並依公司、研發階段、交易類型、治療領域和技術重點進行分類。
  • 自信談判 - 了解頂級公司在以往交易中達成的關鍵條款，助您建立最優合約。
  • 強有力的盡職調查支援 - 進行數據驅動的評估，以確定擬議交易條款對潛在合作夥伴的可行性和競爭力。
  • 研究範圍

本報告 "製藥和生物技術領域的臨床階段合作條款和協議" 提供以下內容：

  • 2020年以來生物製藥產業臨床階段合約簽署趨勢
  • 詳細的合約結構（包括預付款、里程碑付款和特許權使用費條款）
  • 實際臨床階段合約案例研究
  • 訪問超過1670項臨床階段交易（在有合約記錄的情況下）
  • 2020年以來最活躍的臨床階段交易方簡介
  • 最高價值臨床階段交易分析

每筆合約記錄的索引如下：

  • 公司名稱（依字母順序排列）
  • 交易總價值
  • 合約簽署時的研發階段（I期、II期、III期）
  • 交易類型
  • 特定治療領域
  • 關鍵問題解答

本報告透過分析實際合同，清楚解答了以下關鍵問題：

  • 每份合約授予了哪些具體權利？
  • 適用哪些排他性條款？
  • 合約的財務結構是什麼？ （預付款、里程碑付款、特許權使用費）
  • 誰負責開發、生產和商業化？
  • 如何處理知識產權？
  • 合約的終止條件是什麼？
  • 有哪些爭議解決機制？
  • 如何管理保密權和出版權？
  • 閱讀本報告，幫助您獲得競爭優勢。

目錄

摘要整理

第一章：引言

第二章：企業為何與臨床階段化合物合作

  • 引言
  • 合作在臨床階段開發中的作用
    • 臨床階段開發中的許可
    • 臨床階段開發中的許可
  • I期、II期及III期交易的差異
  • 簽訂臨床階段合作協議的原因
    • 授權人簽訂臨床階段交易的原因
    • 被授權人簽訂臨床階段交易的原因
  • 臨床階段合作協議的未來

章節3 臨床階段交易策略與架構

  • 引言
  • 企業在哪個階段開展合作？
    • 製藥/生技領域的早期合作
    • 製藥/生技領域的合作
  • 早期與後期合作－風險與成本比較
  • 企業在臨床階段合作上投入多少資金？
  • 純粹授權和多組件合作協議
  • 純粹授權協議結構
    • 純粹授權協議範例
    • 個案研究 9
    • 個案研究 10
  • 多組件臨床階段合作協議
    • 包含多個組件的臨床階段條款範例
    • 個案研究 11

第四章 臨床階段的合作支付策略

  • 引言
  • 臨床階段的支付策略
  • 付款方式
    • 主要內容
    • 預付款
    • 貸款
    • 轉換貸款
    • 公平性
    • 研發資金
    • 許可費
    • 里程碑付款付款方式
    • 特許權使用費支付
    • Quids
    • 可選付款方式

第五章 臨床階段交易趨勢

  • 引言
  • 長期臨床階段合作關係
    • 2020年以來I期臨床試驗交易趨勢
    • 2020年以來第二期臨床試驗交易趨勢
    • 2020年以來III期臨床試驗交易趨勢
  • 依交易類型劃分的臨床階段合作關係
  • 依疾病區分的臨床階段合作關係
  • 依技術類型劃分的臨床階段合作關係
  • 2020年以來最活躍公司劃分的臨床階段合作關係

第六章 臨床階段合作關係中的付款條款

  • 引言
  • 臨床階段付款指引條款
    • 預付款
    • 里程碑付款
    • 特許權使用費
  • 臨床階段付款條款 - 交易資料分析
    • 公開數據
    • 調查數據
  • 付款條款分析
    • 臨床階段合作項目總價值
    • 臨床階段協議的合約預付款
    • 臨床階段交易的里程碑付款
    • 臨床階段交易的特許權使用費率
  • 臨床階段交易的財務中位數
    • 臨床階段交易的總價值
    • 臨床階段交易的初始價值
    • 臨床階段交易的里程碑價值
    • 臨床階段交易的特許權使用費

第七章 領先的臨床階段交易

  • 引言
  • 依金額排列的關鍵臨床階段交易

第八章 - 擁有臨床階段合約的前 25 家公司

  • 引言
  • 臨床階段合約最活躍的前 25 家公司

第九章 臨床階段合作協議目錄

  • 引言
  • 臨床階段交易數據來自 2020 年

第十章 依研發階段劃分的臨床階段交易

  • 引言
  • 依臨床階段劃分的交易
  • I 期
  • II 期
  • III 期
  • 法規

附錄

  • 附錄 1 - 依公司（AZ）劃分的臨床階段交易
  • 附錄 2 - 依產業劃分的臨床階段交易
  • 附錄 3 - 依研發階段劃分的臨床階段交易
  • 附錄 4 - 依治療領域劃分的臨床階段交易
  • 附錄 5 - 依技術類型劃分的臨床階段交易
  • 關於研究公司
  • 當前合作關係
  • 當前交易
  • 來自 "目前合作關係" 的最新報告標題
簡介目錄
Product Code: CP2058

The Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology report provides a comprehensive, data-driven analysis of how and why companies engage in clinical-stage partnering agreements, as well as the financial and strategic terms shaping these collaborations. This essential industry resource delivers unparalleled insights into deal structures, negotiation dynamics, and financial considerations for clinical-stage drug development partnerships.

At the clinical stage, licensing agreements typically grant the licensee exclusive rights or options to develop a licensor's product or technology, often covering Phase I, Phase II, and Phase III trials. These agreements are frequently multi-component, involving collaborative R&D, co-development, and commercialization strategies.

This report provides detailed intelligence on the latest clinical-stage agreements in the healthcare sector, helping companies evaluate market trends, optimize negotiation strategies, and benchmark deal structures.

A Must-Have Resource for Biotech and Pharma Dealmakers

The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report is an indispensable resource for business development, legal, and financial professionals involved in biopharma dealmaking.

With comprehensive insights, a vast deal database, and direct access to contract documents, this report serves as the ultimate tool for:

  • Benchmarking deal structures and financial terms
  • Optimizing negotiation strategies
  • Assessing potential partners' flexibility
  • Identifying trends in clinical-stage partnerships
  • Why This Report is Essential for Dealmakers
  • Understanding the flexibility and negotiation strategies of potential partners is critical when structuring clinical-stage partnerships. While headline financial terms (e.g., upfront payments, milestones, royalties) provide a broad overview, contract documents reveal the actual triggers and conditions for these payments-details often missing from press releases and traditional deal databases.
  • This report provides a comprehensive listing of over 1,859 clinical-stage deals announced since 2020, including financial terms where available. Additionally, it features direct links to online deal records, along with publicly available contract documents submitted to the SEC.
  • By analyzing these agreements, companies can gain critical insights to refine deal strategies, assess partner flexibility, and structure competitive agreements.
  • Comprehensive Analysis of Clinical-Stage Partnering Trends

The first chapters of this report offer a detailed orientation to clinical-stage deal-making, including:

Chapter 1 - Introduction to the report

Chapter 2 - Why companies engage in clinical-stage partnerships

Chapter 3 - Strategic approaches and deal structures, with case studies

Chapter 4 - Payment strategies, including upfronts, milestones, and royalties

Chapter 5 - Analysis of clinical-stage deal activity categorized by year, stage of development, therapeutic area, technology type, and key dealmakers

Chapter 6 - In-depth financial analysis of headline values, upfront payments, milestone triggers, and royalty rates for Phase I, Phase II, and Phase III deals

Chapter 7 - A review of the leading clinical-stage deals by headline value

Chapter 8 - Profiles of the top 25 most active clinical-stage dealmakers

Chapter 9 - A database of clinical-stage partnering agreements, including contract documents where available

Chapter 10 - A comprehensive directory of all clinical-stage deals categorized by Phase I, Phase II, and Phase III

  • Key Benefits of the Report

This must-have industry resource provides exclusive insights to help companies assess, structure, and negotiate their own clinical-stage partnerships. Key benefits include:

  • Unparalleled Market Insights - Gain a deep understanding of clinical-stage deal trends shaping the pharma and biotech industry since 2020.
  • Exclusive Financial Data Access - Unlock headline values, upfront payments, milestone structures, and royalty terms, giving you a competitive edge in deal negotiations.
  • Comprehensive Deal Database - Access a curated repository of 1,859 clinical-stage agreements, including contract documents where available, for unmatched transparency and benchmarking.
  • Deep-Dive into Industry Leaders - Analyze actual clinical-stage deals entered into by the top 25 global pharma and biotech companies, alongside emerging biopharma players.
  • Proven Case Studies & Structural Analysis - Examine real-world deal structures and case studies to refine your own partnering and negotiation strategies.
  • High-Value Deal Identification - Pinpoint the most lucrative clinical-stage deals signed since 2020, gaining insight into premium industry transactions.
  • Profile the Most Active Dealmakers - Identify the key players driving clinical-stage collaborations, ensuring you target the right partners.
  • Strategic Deal Mapping - Navigate a full A-Z listing of clinical-stage agreements, categorized by company, development phase, deal type, therapeutic area, and technology focus.
  • Negotiate with Confidence - Understand the key terms and conditions top-tier companies have agreed to in previous deals, helping you structure optimal agreements.
  • Robust Due Diligence Support - Conduct data-backed assessments to determine the viability and competitiveness of your proposed deal terms with potential partners.
  • Report Scope

The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides:

  • Trends in clinical-stage dealmaking in the biopharma industry since 2020
  • Detailed deal structures, including upfront, milestone, and royalty terms
  • Case studies of real-life clinical-stage agreements
  • Access to over 1,670 clinical-stage deals, with contract records where available
  • Partnering profiles of the most active clinical-stage dealmakers since 2020
  • Analysis of the highest-value clinical-stage deals

Each deal record is indexed by:

  • Company (A-Z)
  • Headline Value
  • Stage of Development at Signing (Phase I, Phase II, Phase III)
  • Deal Type
  • Specific Therapy Focus
  • Critical Questions Answered

By analyzing actual contract agreements, this report provides definitive answers to critical questions such as:

  • What specific rights are granted in each agreement?
  • What exclusivity terms apply?
  • How is the deal structured financially? (Upfronts, milestones, royalties)
  • Who controls development, manufacturing, and commercialization?
  • How are intellectual property rights handled?
  • What are the termination conditions for the agreement?
  • What dispute resolution mechanisms are in place?
  • How are confidentiality and publication rights managed?
  • Gain the competitive edge-explore the report today.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Why do companies partner clinical stage compounds?

  • 2.1. Introduction
  • 2.2. The role of clinical stage partnering
    • 2.2.1. In-licensing at clinical stage
    • 2.2.2. Out-licensing at clinical stage
  • 2.3. Difference between phase I, II and III stage deals
  • 2.4. Reasons for entering into clinical stage partnering deals
    • 2.4.1. Licensors reasons for entering clinical stage deals
    • 2.4.2. Licensees reasons for entering clinical stage deals
  • 2.5. The future of clinical stage partnering deals

Chapter 3 - Clinical stage deal strategies and structure

  • 3.1. Introduction
  • 3.2. At what stage do companies partner?
    • 3.2.1. Partnering early in pharmaceutical/biotech
    • 3.2.1.1. Discovery and preclinical stage partnering case studies
    • 3.2.1.1.a. Case study 1
    • 3.2.1.1.b. Case study 2
    • 3.2.1.1.c. Case study 3
    • 3.2.1.1.d. Case study 4
    • 3.2.2. Partnering later in pharmaceutical/biotech
    • 3.2.2.1. Clinical stage partnering case studies
    • 3.2.2.1.a. Case study 5
    • 3.2.2.1.b. Case study 6
    • 3.2.2.1.c. Case study 7
    • 3.2.2.1.d. Case study 8
  • 3.3. Early and later stage partnering - a risk/cost comparison
  • 3.4. What do companies spend on clinical stage partnering?
  • 3.5. Pure versus multi-component partnering deals
  • 3.6. Pure licensing agreement structure
    • 3.6.1. Example pure licensing agreements
    • 3.6.1.a. Case study 9
    • 3.6.1.b. Case study 10
  • 3.7. Multicomponent clinical stage partnering agreements
    • 3.7.1. Example multicomponent clinical stage clauses
    • 3.7.1.a. Case study 11

Chapter 4 - Clinical stage partnering payment strategies

  • 4.1. Introduction
  • 4.2. Clinical stage payment strategies
  • 4.3. Payment options
    • 4.3.1. Headline values
    • 4.3.2. Upfront payments
    • 4.3.2.1. Conditionality of upfront payments
    • 4.3.3. Loans
    • 4.3.4. Convertible loans
    • 4.3.5. Equity
    • 4.3.6. R&D funding
    • 4.3.7. Licensing fees
    • 4.3.8. Milestone payments
    • 4.3.9. Royalty payments
    • 4.3.9.1. Issues affecting royalty rates
    • 4.3.9.2. Royalties on combination products
    • 4.3.9.2.a. Case study 12
    • 4.3.9.3. Guaranteed minimum/maximum annual payments
    • 4.3.9.4. Royalty stacking
    • 4.3.9.5. Royalties and supply/purchase contracts
    • 4.3.10. Quids
    • 4.3.11. Option payments

Chapter 5 - Trends in clinical stage deal making

  • 5.1. Introduction
  • 5.2. Clinical stage partnering over the years
    • 5.2.1. Trends in phase I deals since 2020
    • 5.2.1.1. Attributes of phase I deals
    • 5.2.2. Trends in phase II deals since 2020
    • 5.2.2.2. Attributes of phase II deals
    • 5.2.3. Trends in phase III deals since 2020
    • 5.2.3.1. Attributes of phase III deals
  • 5.3. Clinical stage partnering by deal type
  • 5.4. Clinical stage partnering by disease type
  • 5.5. Partnering by clinical stage technology type
  • 5.6. Clinical stage partnering by most active company since 2020

Chapter 6 - Payment terms for clinical stage partnering

  • 6.1. Introduction
  • 6.2. Guidelines for clinical stage payment terms
    • 6.2.1. Upfront payments
    • 6.2.2. Milestone payments
    • 6.2.3. Royalty payments
  • 6.3. Clinical stage payment terms - deal data analysis
    • 6.3.1. Public data
    • 6.3.2. Survey data
  • 6.4. Payment terms analysis
    • 6.4.1. Clinical stage partnering headline values
    • 6.4.2. Clinical stage deal upfront payments
    • 6.4.3. Clinical stage deal milestone payments
    • 6.4.4. Clinical stage royalty rates
  • 6.5 Clinical stage median financials
    • 6.5.1. Clinical stage headline value
    • 6.5.2. Clinical stage upfront value
    • 6.5.3. Clinical stage milestone value
    • 6.5.4. Clinical stage royalty value

Chapter 7 - Leading clinical stage deals

  • 7.1. Introduction
  • 7.2. Top clinical stage deals by value

Chapter 8 - Top 25 most active clinical stage dealmakers

  • 8.1. Introduction
  • 8.2. Top 25 most active clinical stage dealmakers

Chapter 9 - Clinical stage partnering contracts directory

  • 9.1. Introduction
  • 9.2. Clinical stage deals with contracts since 2020

Chapter 10 - Clinical stage deal making by development stage

  • 10.1. Introduction
  • 10.2. Deals by clinical stage
  • Phase I
  • Phase II
  • Phase III
  • Regulatory

Appendices

  • Appendix 1 - Clinical stage dealmaking by companies A-Z
  • Appendix 2 - Clinical stage dealmaking by industry sector
  • Appendix 3 - Clinical stage dealmaking by stage of development
  • Appendix 4 - Clinical stage dealmaking by therapy area
  • Appendix 5 - Clinical stage dealmaking by technology type
  • About Biopharma Research Ltd
  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Definition of clinical phases in dealmaking
  • Figure 2: Components of the pure licensing deal structure
  • Figure 3: Payment options for clinical stage partnering deals
  • Figure 4: Issues affecting royalty rates
  • Figure 5: Clinical stage partnering by deal type
  • Figure 6: Clinical stage partnering by disease type
  • Figure 7: Clinical stage partnering by technology type
  • Figure 8: Top 25 most active clinical stage dealmakers
  • Figure 9: Review of upfront payments for clinical stage deals
  • Figure 10: Review of milestone payments for clinical stage deals
  • Figure 11: Review of royalty payments for clinical stage deals
  • Figure 12: Clinical stage deals with a headline value
  • Figure 13: Clinical stage deals with an upfront value
  • Figure 14: Clinical stage deals with a milestone value
  • Figure 15: Clinical stage deals with a royalty rate value
  • Figure 16: Top clinical stage deals by value
  • Figure 17: Most active clinical stage dealmakers